CNBC Utilities Page Drugs

More

  • Merrimack CEO: Face of pharma isn't a bad actor Thursday, 4 Feb 2016 | 2:14 PM ET
    Merrimack CEO: Face of pharma isn't a bad actor

    Merrimack Pharmaceuticals develops products to treat cancer. President and CEO Bob Mulroy, shares his view of drug price hikes and whether the FDA is in the way of companies.

  • Chaffetz: 'Sort of childlike' behavior from Shkreli Thursday, 4 Feb 2016 | 1:55 PM ET
    Chaffetz: 'Sort of childlike' behavior from Shkreli

    Rep. Jason Chaffetz (R-Utah), Chairman of the House Oversight & Government Committee, comments on former Turing Pharmaceuticals CEO Martin Shkreli's tweet calling the Congressional committee "imbeciles."

  • Chaffetz: Believe in profit, but I take issue with misrepresenting drugs

    Rep. Jason Chaffetz (R-Utah), Chairman of the House Oversight & Government Committee, reflects on former Turing Pharmaceuticals CEO Martin Shkreli's behavior on Capitol Hill, and the debate on drug prices and the role of government.

  • Soaring drug prices: What can Congress do? Thursday, 4 Feb 2016 | 1:02 PM ET
    Soaring drug prices: What can Congress do?

    CNBC's Eamon Javers reports on government involvement in drug prices.

  • Shkreli tweets after pleading Fifth Thursday, 4 Feb 2016 | 10:20 AM ET
    Shkreli tweets after pleading Fifth

    Former Turing Pharmaceuticals CEO Martin Shkreli has tweeted after being excused from a drug price hearing on Capitol Hill. He says "it is hard to accept that these imbeciles represent the people in our government."

  • Drug prices debate Thursday, 4 Feb 2016 | 10:12 AM ET
    Drug prices debate

    CNBC's Meg Tirrell reports from Capitol Hill, where former Turing Pharmaceuticals CEO Martin Shkreli's invoked the Fifth Amendment at a drug price hike hearing.

  • Rep. Gowdy to Shkreli's attorney: You will be seated Thursday, 4 Feb 2016 | 10:06 AM ET
    Rep. Gowdy to Shkreli's attorney: You wil be seated

    Former Turing Pharmaceuticals CEO Martin Shkreli pleads the Fifth Amendment before Congress, and Shkreli's Attorney Benjamin Brafman attempts to address Congress.

  • Attorney: No disrespect, just 'nervous energy' by Shkreli

    Former Turing Pharmaceuticals CEO Martin Shkreli's Attorney Benjamin Brafman speaks to the press after Shkreli was excused from a House panel hearing.

  • Jim Cramer on Brafman's attempt: My breath is taken away

    Martin Shkreli's Attorney Benjamin Brafman attempted to address Congress in a hearing on drug price hikes, in which he was told to be seated. CNBC's Jim Cramer weighs in.

  • Martin Shkreli excused from hearing Thursday, 4 Feb 2016 | 9:54 AM ET
    Martin Shkreli excused from hearing

    Former Turing Pharmaceuticals CEO Martin Shkreli is escorted out after pleading the Fifth Amendment in his testimony before the House Oversight Committee hearing on drug price hikes.

  • Cummings to Shkreli: You could change the system Thursday, 4 Feb 2016 | 9:49 AM ET
    Cummings to Shkreli: You could change the system, are you listening?

    Rep. Elijah Cummings presses former Turing Pharmaceuticals CEO Martin Shkreli on Capitol Hill, as he testifies before the House Oversight Committee hearing on drug price hikes, invoking the Fifth Amendment.

  • Shkreli pleads the Fifth Thursday, 4 Feb 2016 | 9:41 AM ET
    Martin Shkreli, former CEO of Turing Pharmaceuticals LLC, is sworn in before a House Oversight and Government Reform hearing on "Developments in the Prescription Drug Market Oversight" on Capitol Hill in Washington February 4, 2016.

    Former Turing Pharmaceuticals CEO Martin Shkreli testifies before the House Oversight Committee hearing on drug price hikes, invoking the Fifth Amendment.

  • Congress presses Martin Shkreli on drug prices Thursday, 4 Feb 2016 | 9:40 AM ET
    Congress presses Martin Shkreli on drug prices

    Former Turing Pharmaceuticals CEO Martin Shkreli testifies before the House Oversight Committee hearing on drug price hikes, invoking the Fifth Amendment.

  • Martin Shkreli on the Hill Thursday, 4 Feb 2016 | 9:20 AM ET
    Martin Shkreli on the Hill

    House Oversight Chairman Jason Chaffetz swears in the panel at the House Oversight Committee hearing on drug price hikes, where former Turing Pharmaceuticals CEO Martin Shkreli is testifying.

  • Jim Cramer: Drug price hearing 'not for show' Thursday, 4 Feb 2016 | 9:06 AM ET
    Jim Cramer: Drug price hearing 'not for show'

    The "Squawk on the Street" crew discuss the House Oversight Committee hearing on drug price hikes, where former Turing Pharmaceuticals CEO Martin Shkreli, and Valeant Pharmaceuticals interim CEO Howard Schiller are testifying.

  • President Barack Obama will push for $1.1 billion in new funding to expand treatment for the fast-growing number of people addicted to heroin and prescription pain killers, the White House said on Tuesday. In 2014, a record number of Americans died from drug overdoses, with the highest rates seen in West Virginia, New Mexico, New Hampshire, Kentucky and Ohio.

  • WASHINGTON, Feb 2- President Barack Obama will ask the U.S. Congress for $1.1 billion in new funding to expand treatment for people addicted to heroin and prescription pain killers, the White House said, a push to address an epidemic that has become a major issue in the 2016 presidential election campaign.

  • New dark truth behind white mortality Friday, 29 Jan 2016 | 12:01 AM ET
    Heart rate monitor

    Common illnesses like heart disease, diabetes and respiratory conditions are causing more of the increase in deaths.

  • Robert Califf, is a cardiologist and researcher who joined the FDA a year ago as a deputy commissioner. Califf's extensive ties to the pharmaceutical industry give me no reason to believe that he would make the FDA work for ordinary Americans, rather than just the CEOs of pharmaceutical companies, "Sanders said in a statement. Peter Pitts, a former associate...

  • Robert Califf, is a cardiologist and researcher who joined the FDA a year ago as a deputy commissioner. Califf's extensive ties to the pharmaceutical industry give me no reason to believe that he would make the FDA work for ordinary Americans, rather than just the CEOs of pharmaceutical companies, "Sanders said in a statement. The Senate Committee on Health,...